A targeted MAVS fusion protein for controlled innate immune activation and antitumor therapy
Targeted therapies leveraging the innate immune system are emerging as promising cancer treatments. The mitochondrial antiviral signaling protein (MAVS) plays a crucial role in initiating innate immune responses, but its clinical use is limited by the risk of uncontrolled activation and systemic tox...
Збережено в:
| Автори: | , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Taylor & Francis Group
2025-12-01
|
| Серія: | OncoImmunology |
| Предмети: | |
| Онлайн доступ: | https://www.tandfonline.com/doi/10.1080/2162402X.2025.2478850 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|